Labat Africa (JSE:LAB) YoY EBITDA Growth: 387.50% (As of Nov. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Labat Africa YoY EBITDA Growth?

Labat Africa JSE:LAB YoY EBITDA Growth is 387.50% as of Nov. 2025. The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Labat Africa's YoY EBITDA Growth for the quarter that ended in Nov. 2025 was 387.50%.

Labat Africa's EBITDA per Share for the six months ended in Nov. 2025 was R0.08.

Labat Africa YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Labat Africa's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labat Africa YoY EBITDA Growth Chart

Labat Africa Annual Data
Trend Feb14 Feb15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 May23 May24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -144.44 -54.17 116.22 -1,966.67 75.00

Labat Africa Semi-Annual Data
Aug15 Aug16 Feb17 Aug17 Feb18 Aug18 Feb19 Aug19 Feb20 Aug20 Feb21 Aug21 Feb22 Nov22 May23 Nov23 May24 Nov24 May25 Nov25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.75 63.41 -15.79 266.67 387.50

Labat Africa YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Labat Africa's YoY EBITDA Growth for the fiscal year that ended in May. 2024 is calculated as:

YoY EBITDA Growth (A: May. 2024 )
=(EBITDA per Share (A: May. 2024 )-EBITDA per Share (A: May. 2023 ))/ | EBITDA per Share (A: May. 2023 ) |
=(-0.028--0.112)/ | -0.112 |
=75.00 %

Labat Africa's YoY EBITDA Growth for the quarter that ended in Nov. 2025 is calculated as:

YoY EBITDA Growth (Q: Nov. 2025 )
=(EBITDA per Share (Q: Nov. 2025 )-EBITDA per Share (Q: Nov. 2024 )) / | EBITDA per Share (Q: Nov. 2024 )) |
=(0.078-0.016)/ | 0.016 |
=387.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 387.50% mean?
Labat Africa (JSE:LAB) has a YoY EBITDA Growth of 387.50% as of Nov. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Labat Africa and its competitors.
Is Labat Africa's YoY EBITDA Growth too high?
Labat Africa's current YoY EBITDA Growth is 387.50%.
How does Labat Africa's YoY EBITDA Growth compare to ZTS and UTHR?
Labat Africa's YoY EBITDA Growth of 387.50% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Labat Africa and its competitors. Labat Africa's current YoY EBITDA Growth is 387.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.18, compared to a current price of R0.03 — trading 83.3% below its estimated fair value. The current YoY EBITDA Growth is 387.50%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current YoY EBITDA Growth is 387.50% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Labat Africa Business Description

Other Exchanges LAO:Germany
Address 75 Maude StreetSandown, The Leonardo 14th Floor, Sandown, Johannesburg, GT, ZAF, 1709
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.